Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis
Condition(s):AngiomyolipomaLast Updated:March 8, 2012Completed
Hide Studies Not Open or Pending
Condition(s):AngiomyolipomaLast Updated:March 8, 2012Completed
Condition(s):Renal AngiomyolipomaLast Updated:November 18, 2023Recruiting
Condition(s):Sporadic Angiomyolipomas (AMLs)Last Updated:December 15, 2022Terminated
Condition(s):Renal AngiomyolipomaLast Updated:September 9, 2021Completed
Condition(s):Renal Angiomyolipomas; Tuberous SclerosisLast Updated:January 23, 2018Completed
Condition(s):Nonmalignant Neoplasm; Tuberous Sclerosis; Lymphangioleimyomatosis; Kidney AngiomyolipomaLast Updated:April 25, 2022Completed
Condition(s):Tuberous Sclerosis; Lymphangioleiomyomatosis; AngiomyolipomaLast Updated:August 4, 2022Completed
Condition(s):Tuberous Sclerosis ComplexLast Updated:January 5, 2024Recruiting
Condition(s):Tuberous Sclerosis Complex (TSC); Lymphangioleiomyomatosis (LAM)Last Updated:February 17, 2017Completed
Condition(s):Tuberous Sclerosis; LymphangioleiomyomatosisLast Updated:September 25, 2013Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.